Features | Partner Sites | Information | LinkXpress
Sign In
JIB
GLOBETECH PUBLISHING
BioConferenceLive

Experimental Drug Reverses Cognitive Impairment in Aged Alzheimer's Disease Mice

By BiotechDaily International staff writers
Posted on 29 May 2013
Image: Senior author Dr. Dave Schubert (Photo courtesy of the Salk Institute for Biological Studies).
Image: Senior author Dr. Dave Schubert (Photo courtesy of the Salk Institute for Biological Studies).
Image: First author Dr. Marguerite Prior holding ampoule of the J147 drug (Photo courtesy of the Salk Institute for Biological Studies).
Image: First author Dr. Marguerite Prior holding ampoule of the J147 drug (Photo courtesy of the Salk Institute for Biological Studies).
Image: Salk Institute scientists developed J147, a synthetic drug shown to improve memory and prevent brain damage in mice with Alzheimer's disease (Photo courtesy of the Salk Institute for Biological Studies).
Image: Salk Institute scientists developed J147, a synthetic drug shown to improve memory and prevent brain damage in mice with Alzheimer's disease (Photo courtesy of the Salk Institute for Biological Studies).
An experimental drug for treatment of Alzheimer's disease (AD) gave excellent results in a mouse model of the disease and is expected to be tested in clinical trials leading to its eventual use in humans.

The drug, J147, is an orally bioavailable, blood brain-barrier permeable benzylidine-acetohydrazide compound proven safe in mice that was developed by researchers at the Salk Institute for Biological Studies (La Jolla, CA, USA). The potential of J147 for treatment of AD was discovered during a screening process using cultured neurons, a system that mimicked the brain of a patient with advanced AD.

In the current study, Salk Institute investigators treated aged AD mice with J147. Cognitive behavioral assays, histology, ELISA, and Western blotting were used to assay the effect of J147 on memory, amyloid metabolism, and neuroprotective pathways. J147 was also investigated in a scopolamine-induced model of memory impairment and compared to the drug donepezil, the most widely prescribed compound for treatment of AD.

Results published in the May 14, 2013, online edition of the journal Alzheimer's Research and Therapy revealed that J147 had the ability to rescue cognitive deficits when administered at a late stage in the disease. The ability of J147 to improve memory in aged AD mice was correlated with its induction of the neurotrophic factors NGF (nerve growth factor) and BDNF (brain derived neurotrophic factor) as well as several BDNF-responsive proteins that are important for learning and memory.

The comparison between J147 and donepezil in the scopolamine model showed that while both compounds were comparable at rescuing short term memory, J147 was superior at rescuing spatial memory and a combination of the two worked best for contextual and cued memory.

"Alzheimer's disease research has traditionally focused on a single target, the amyloid pathway," said senior author Dr. Dave Schubert, professor of cellular neurobiology at the Salk Institute for Biological Studies, "but unfortunately drugs that have been developed through this pathway have not been successful in clinical trials. Our approach is based on the pathologies associated with old age - the greatest risk factor for Alzheimer's and other neurodegenerative diseases - rather than only the specificities of the disease."

"In addition to yielding an exceptionally promising therapeutic, both the strategy of using mice with existing disease and the drug discovery process based upon aging are what make the study interesting and exciting," said Dr. Schubert, "because it more closely resembles what happens in humans, who have advanced pathology when diagnosis occurs and treatment begins. Most studies test drugs before pathology is present, which is preventive rather than therapeutic and may be the reason drugs do not transfer from animal studies to humans."

Related Links:

Salk Institute for Biological Studies




comments powered by Disqus

Channels

Genomics/Proteomics

view channel
Image: In the liver tissue of obese animals with type II diabetes, unhealthy, fat-filled cells are prolific (small white cells, panel A). After chronic treatment through FGF1 injections, the liver cells successfully lose fat and absorb sugar from the bloodstream (small purple cells, panel B) and more closely resemble cells of normal, non-diabetic animals (Photo courtesy of the Salk Institute for Biological Studies).

Fibroblast Growth Factor 1 Treatment Restores Glucose Control in Mouse Diabetes Model

A "vaccine" based on the metabolic regulator fibroblast growth factor 1 (FGF1) removed the insulin resistance that characterizes type II diabetes and restored the body's natural ability to manage its glucose... Read more

Therapeutics

view channel
Image: This type of electronic pacemaker could become obsolete if induction of biological pacemaker cells by gene therapy proves successful (Photo courtesy of Wikimedia Commons).

Gene Therapy Induces Functional Pacemaker Cells in Pig Heart Failure Model

Cardiovascular disease researchers working with a porcine heart failure model have demonstrated the practicality of using gene therapy to replace implanted electronic pacemakers to regulate heartbeat.... Read more

Lab Technologies

view channel

Precise Ion Irradiation Dosing Method Developed for Cancer Therapy

Scientists are employing nuclear physics principles to provide more effective approaches to radiotherapy treatment for cancer patients. Radiation therapy using heavy ions is best suitable for cancer patients with tumors that are difficult to access, such as in the brain. These particles scarcely damage the penetrated... Read more

Business

view channel

Cancer Immunotherapy Sector Predicted to Surge to USD 9 Billion Across Major Pharma Through 2022

The immunotherapy market will experience substantial growth through 2022, increasing from USD 1.1 billion in 2012 to nearly USD 9 billion in 2022 (corresponding to 23.8% annual growth) in the United Kingdom, United States, France, Germany, Italy, Spain, and Japan, according to recent market research. This notable growth... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.